Health Tidings Policy & AcquisitionsExclusive: Boehringer Ingelheim Acquires Sitryx Program in High-Value Autoi... Exclusive: Boehringer Ingelheim Acquires Sitryx Program in High-Value Autoi... Read Post »
Health TidingsGilead’s Bictegravir/Lenacapavir FDC Shows Week 48 Promise in ARTISTR... Gilead’s Bictegravir/Lenacapavir FDC Shows Week 48 Promise in ARTISTR... Read Post »
Clinical TrailsGalderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo No... Galderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo No... Read Post »
Health TidingsViiV Healthcare Unveils Promising Phase 1 Data for Two Ultra Long-Acting HI... ViiV Healthcare Unveils Promising Phase 1 Data for Two Ultra Long-Acting HI... Read Post »
Clinical TrailsPalvella Announces Topline Win for QTORIN in Microcystic Lymphatic Malforma... Palvella Announces Topline Win for QTORIN in Microcystic Lymphatic Malforma... Read Post »
Clinical TrailsArgenx Reports Improved Ocular Symptoms in MG with Subcutaneous VYVGART Argenx Reports Improved Ocular Symptoms in MG with Subcutaneous VYVGART Read Post »
Health TidingsGSK’s Bepirovirsen NDA Accepted in Japan for Chronic Hepatitis B GSK’s Bepirovirsen NDA Accepted in Japan for Chronic Hepatitis B Read Post »
Clinical TrailsEli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 ... Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 ... Read Post »
New Drug ApprovalJ&J Seeks FDA Approval of IMAAVY® as First Treatment for wAIHA J&J Seeks FDA Approval of IMAAVY® as First Treatment for wAIHA Read Post »
Health TidingsGSK’s Linerixibat Gains NMPA Priority Review in China for Itch in Rar... GSK’s Linerixibat Gains NMPA Priority Review in China for Itch in Rar... Read Post »
Clinical TrailsViiV’s Lotivibart Hits 94% HIV Control at 12 Months EMBRACE Data ViiV’s Lotivibart Hits 94% HIV Control at 12 Months EMBRACE Data Read Post »
Clinical TrailsAxsome Therapeutics Doses First Patient in CLARITY Phase 3 Trial Axsome Therapeutics Doses First Patient in CLARITY Phase 3 Trial Read Post »
Health Tidings Policy & AcquisitionsBeam Therapeutics Advances BEAM-304 for PKU and Pfizer Collaboration Beam Therapeutics Advances BEAM-304 for PKU and Pfizer Collaboration Read Post »
Health Tidings Policy & AcquisitionsNovo Nordisk Partners with Vivtex to Pioneer Oral Biologics for Obesity and... Novo Nordisk Partners with Vivtex to Pioneer Oral Biologics for Obesity and... Read Post »
Health Tidings Policy & AcquisitionsGSK Acquires 35Pharma for $950M to Advance HS235 in Pulmonary Hypertension ... GSK Acquires 35Pharma for $950M to Advance HS235 in Pulmonary Hypertension ... Read Post »
Clinical TrailsPromising Phase 3 Data for Merck’s Doravirine/Islatravir Combo in HIV Promising Phase 3 Data for Merck’s Doravirine/Islatravir Combo in HIV Read Post »
Drugs Safety AlertFDA Halts New Enrollment in MacroGenics’ Lorigerlimab Trial Over Safe... FDA Halts New Enrollment in MacroGenics’ Lorigerlimab Trial Over Safe... Read Post »
Clinical TrailsBristol Myers Squibb’s Reblozyl Shows Promise in Alpha-Thalassemia: P... Bristol Myers Squibb’s Reblozyl Shows Promise in Alpha-Thalassemia: P... Read Post »
Health TidingsViatris Phentolamine Drops Advance to FDA Review for Presbyopia Treatment Viatris Phentolamine Drops Advance to FDA Review for Presbyopia Treatment Read Post »
New Drug ApprovalFDA Grants Full Approval to Pfizer’s BRAFTOVI Regimen FDA Grants Full Approval to Pfizer’s BRAFTOVI Regimen Read Post »
Health TidingsOno Expands Opdivo® Reach: New Korean Approval for MSI-High CRC Ono Expands Opdivo® Reach: New Korean Approval for MSI-High CRC Read Post »
New Drug ApprovalDupixent Approved by FDA: Sanofi & Regeneron’s First Treatment fo... Dupixent Approved by FDA: Sanofi & Regeneron’s First Treatment fo... Read Post »
Clinical TrailsNovartis RWE: Pluvicto Delivers 13.5-Month PFS in ARPI-Pre-Treated mCRPC Novartis RWE: Pluvicto Delivers 13.5-Month PFS in ARPI-Pre-Treated mCRPC Read Post »
Health Tidings Policy & AcquisitionsAstellas and Vir Biotechnology Unite to Advance VIR-5500, a Next-Gen T-Cell... Astellas and Vir Biotechnology Unite to Advance VIR-5500, a Next-Gen T-Cell... Read Post »
Health TidingsTeva/Medincell Advance: SOLARIS-Backed TEV-‘749 NDA Accepted by FDA Teva/Medincell Advance: SOLARIS-Backed TEV-‘749 NDA Accepted by FDA Read Post »
Health TidingsNovo Nordisk Slashes List Prices of Wegovy, Ozempic, and Rybelsus by Up to ... Novo Nordisk Slashes List Prices of Wegovy, Ozempic, and Rybelsus by Up to ... Read Post »
Clinical TrailsNovo Nordisk-Backed Triple Agonist UBT251 Delivers Strong Phase 2 Results i... Novo Nordisk-Backed Triple Agonist UBT251 Delivers Strong Phase 2 Results i... Read Post »
Health Tidings Policy & AcquisitionsOrganon Licenses MIUDELLA®: New Hormone-Free Copper IUD Option Organon Licenses MIUDELLA®: New Hormone-Free Copper IUD Option Read Post »
Health TidingsFlexible SC Amivantamab Regimens Now Authorized EU-Wide for EGFR-Mutant Lun... Flexible SC Amivantamab Regimens Now Authorized EU-Wide for EGFR-Mutant Lun... Read Post »
Clinical TrailsMoonLake’s SLK Shows Strong Results in Phase 2 Trial for Axial Spondy... MoonLake’s SLK Shows Strong Results in Phase 2 Trial for Axial Spondy... Read Post »
Clinical TrailsGossamer Bio’s PROSERA Trial: Narrow Miss on 6MWD, Strong in Advanced... Gossamer Bio’s PROSERA Trial: Narrow Miss on 6MWD, Strong in Advanced... Read Post »
Clinical TrailsCagriSema Delivers 23% Weight Loss in REDEFINE 4: Strong Efficacy, Just Shy... CagriSema Delivers 23% Weight Loss in REDEFINE 4: Strong Efficacy, Just Shy... Read Post »
Health TidingsUltragenyx Scores FDA Priority Review for DTX401 in Rare Metabolic Disorder Ultragenyx Scores FDA Priority Review for DTX401 in Rare Metabolic Disorder Read Post »
New Drug ApprovalFDA Approves Zepbound 4-Dose KwikPen for Obesity Care FDA Approves Zepbound 4-Dose KwikPen for Obesity Care Read Post »
Clinical Trails Policy & AcquisitionsGilead Snaps Up Arcellx, Eyes Anito-cel Approval in Multiple Myeloma Gilead Snaps Up Arcellx, Eyes Anito-cel Approval in Multiple Myeloma Read Post »
Health TidingsEMA Validates ENHERTU® for Post-Neoadjuvant HER2+ Breast Cancer EMA Validates ENHERTU® for Post-Neoadjuvant HER2+ Breast Cancer Read Post »
Clinical TrailsFrom Week 44 to 140: New TREMFYA® Evidence Reinforces Long-Term UC Control... From Week 44 to 140: New TREMFYA® Evidence Reinforces Long-Term UC Control... Read Post »
Health TidingsSetback for Corcept as Court Backs Teva in Korlym Generic Fight Setback for Corcept as Court Backs Teva in Korlym Generic Fight Read Post »
Health TidingsRoche’s Giredestrant NDA Accepted by FDA for ESR1-Mutated Breast Canc... Roche’s Giredestrant NDA Accepted by FDA for ESR1-Mutated Breast Canc... Read Post »
FoodPeanut Butter: A Balanced Look at Its Health Benefits, Risks, and Everyday ... Peanut Butter: A Balanced Look at Its Health Benefits, Risks, and Everyday ... Read Post »
Drugs Safety AlertNew GBS Safety Information Added to GSK’s SHINGRIX Label New GBS Safety Information Added to GSK’s SHINGRIX Label Read Post »
Health TidingsSavara’s MOLBREEVI BLA Accepted by FDA with Priority Review for Rare ... Savara’s MOLBREEVI BLA Accepted by FDA with Priority Review for Rare ... Read Post »
Health TidingsOne High-Quality Trial, Not Two: what the FDA changed and what it means One High-Quality Trial, Not Two: what the FDA changed and what it means Read Post »
Health TidingsOutlook Therapeutics Partners with Mediconsult for Exclusive LYTENAVA™ Di... Outlook Therapeutics Partners with Mediconsult for Exclusive LYTENAVA™ Di... Read Post »
New Drug ApprovalFDA Approves BYSANTI™: A New Ally in Bipolar I and Schizophrenia Treatmen... FDA Approves BYSANTI™: A New Ally in Bipolar I and Schizophrenia Treatmen... Read Post »
New Drug ApprovalChugai report Anti-CD20 Monoclonal Antibody Rituxan® Approved for AIHA Chugai report Anti-CD20 Monoclonal Antibody Rituxan® Approved for AIHA Read Post »
Clinical TrailsTakeda KEPLER Trial: Promising Vedolizumab Results for Pediatric Ulcerative... Takeda KEPLER Trial: Promising Vedolizumab Results for Pediatric Ulcerative... Read Post »
Health TidingsChugai Launches ELEVIDYS in Japan for Duchenne Muscular Dystrophy Chugai Launches ELEVIDYS in Japan for Duchenne Muscular Dystrophy Read Post »
Health TidingsRYBREVANT FASPRO™ Shines in First-Line HNSCC with 56% Response Rate RYBREVANT FASPRO™ Shines in First-Line HNSCC with 56% Response Rate Read Post »
Health TidingsOmvoh Sets New IBD Standard: 3-Year Data + Lilly’s Combination Pipeli... Omvoh Sets New IBD Standard: 3-Year Data + Lilly’s Combination Pipeli... Read Post »
